Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
21 hedge funds and large institutions have $341K invested in Statera Biopharma, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more funds holding
Funds holding: 19 → 21 (+2)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
13% less capital invested
Capital invested by funds: $394K → $341K (-$53K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$65.7K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$37.1K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$4.83K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.41K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.8K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$182 |
| 3 |
Morgan Stanley
New York
|
-$11 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $143K | -$12.8K | -5,815 | -7% |
|
|
LTFS
2
Ladenburg Thalmann Financial Services
Miami,
Florida
| $76K | +$4.83K | +2,200 | +6% |
|
|
3
Citadel Advisors
Miami,
Florida
| $52K | +$65.7K | +29,899 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $29K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| $28K | +$37.1K | +16,877 | New |
|
|
BA
6
BlackRock Advisors
Wilmington,
Delaware
| $5K | – | – | – |
|
|
7
Morgan Stanley
New York
| $2K | -$11 | -5 | -0.4% |
|
|
8
UBS Group
Zurich,
Switzerland
| $2K | +$2.41K | +1,095 | +1,095% |
|
|
IA
9
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
WA
10
Winfield Associates
Cleveland,
Ohio
| $1K | – | – | – |
|
|
BFA
11
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$125 | +57 | +8% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $1K | +$1.32K | +599 | New |
|
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$182 | -83 | -95% |
|
STAB Hedge Fund Activity: Q3 2016 in Review
21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2016, worth a combined $341K — down 13% from $394K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new STAB positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $65.7K. The largest seller was Vanguard Group, cutting an estimated $12.8K.
- 21 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2016, up from 19 in Q2 2016.
- Funds reported $341K of Statera Biopharma, Inc. Common Stock stock for Q3 2016, down 13% quarter-over-quarter.
- 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2016 and 1 closed out, a net change of +2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2016 was Citadel Advisors, an estimated $65.7K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2016 was Vanguard Group, an estimated $12.8K sold.
Based on aggregated 13F filings for Q3 2016.